The interruption of amino acids supply has emerged as a promising anti-tumor strategy, with research focusing on the metabolic vulnerabilities of cancer cells. Depletion of essential amino acids necessary for tumor growth has shown potential in inhibiting cancer cell proliferation and inducing cell death. This approach has garnered significant interest in the field of cancer metabolism and targeted therapies, with studies exploring the mechanisms underlying amino acid depletion’s anti-tumor effects and its potential as a therapeutic strategy across different cancer types.

Advancing our collective understanding in this area is crucial for identifying novel therapeutic targets and developing effective anti-cancer interventions. Recent advances have elucidated the intricate metabolic pathways involved in amino acid utilization by cancer cells, shedding light on the potential for targeted disruption of amino acid metabolism and supply as a strategy to impede tumor growth. Furthermore, studies have highlighted the interplay between amino acid depletion and the tumor microenvironment, offering insights into the broader implications of this approach for cancer therapy.

Original Research articles and reviews in this field are invited.

This Collection supports and amplifies research related to SDG 3 (Good Health and Well-being).

Incretin-based peptide therapeutics, particularly those targeting GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide) receptors, have emerged as pivotal players in the management of metabolic disorders such as type 2 diabetes and obesity. These peptides are integral to the regulation of glucose metabolism and appetite control, making them ideal candidates for therapeutic intervention. Recent developments in peptide modulation have demonstrated promising results, with novel agonists and dual receptor modulators showing enhanced efficacy in clinical trials, paving the way for innovative treatment options.

Understanding the mechanisms underlying GLP-1 and GIP receptor modulation is crucial, as it not only provides insight into metabolic regulation but also reveals potential pathways for novel therapeutic strategies. Advances in this field have led to the development of long-acting formulations and combinatorial approaches that improve patient compliance and therapeutic outcomes. As the global prevalence of obesity and diabetes continues to rise, ongoing research in incretin-based therapies holds the promise of addressing these critical public health challenges.

Future research may lead to groundbreaking discoveries in incretin-based therapeutics, with a focus on personalized medicine approaches that consider individual patient profiles. Enhanced understanding of receptor interactions and the discovery of novel peptide structures could lead to the development of next-generation drugs that provide superior efficacy and safety profiles. Furthermore, advances in drug delivery systems may improve the bioavailability and effectiveness of these therapies, ultimately transforming the treatment landscape for metabolic disorders.

This Collection supports and amplifies research related to SDG 3 (Good Health and Well-being).